Brokerages Set Immatics N.V. (NASDAQ:IMTX) PT at $19.00

Immatics N.V. (NASDAQ:IMTX) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

A number of equities research analysts recently issued reports on IMTX shares. Mizuho set a $25.00 target price on shares of Immatics in a research note on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Jefferies Financial Group initiated coverage on shares of Immatics in a research note on Monday, March 16th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research note on Monday, March 9th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. grew its holdings in shares of Immatics by 10.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock worth $225,322,000 after purchasing an additional 2,075,987 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in shares of Immatics by 43.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock worth $278,000 after purchasing an additional 7,965 shares during the last quarter. SummitTX Capital L.P. grew its holdings in Immatics by 117.7% during the 4th quarter. SummitTX Capital L.P. now owns 96,784 shares of the company’s stock worth $1,016,000 after acquiring an additional 52,318 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in Immatics during the 4th quarter worth about $575,000. Finally, Sphera Funds Management LTD. grew its holdings in Immatics by 47.7% during the 4th quarter. Sphera Funds Management LTD. now owns 861,105 shares of the company’s stock worth $9,042,000 after acquiring an additional 278,000 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors.

Immatics Stock Up 0.7%

Immatics stock opened at $11.25 on Friday. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -6.11 and a beta of 1.34. The firm’s fifty day moving average is $10.09 and its 200 day moving average is $10.04. Immatics has a 52-week low of $3.94 and a 52-week high of $12.41.

Immatics (NASDAQ:IMTX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14. The company had revenue of $23.00 million for the quarter, compared to the consensus estimate of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. On average, equities research analysts anticipate that Immatics will post -1.49 earnings per share for the current fiscal year.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.